Iovance Biotherapeutics Inc Net Income per Employee (IOVA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Iovance Biotherapeutics inc   (NASDAQ: IOVA)
 

Iovance Biotherapeutics Inc Net Income per Employee

IOVA's Quarterly Results, Trends, Rankings, Statistics
Iovance Biotherapeutics Inc recorded a cumulative net loss of $-354 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 42 other companies achieving higher income per employee. While Iovance Biotherapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2725 to 3328.


What is Income per Employee Ratio?






IOVA Net Income per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -362,933 -401,003 -407,829 -399,919 -384,989
IOVA's Total Ranking # 3328 # 2725 # 3614 # 3435 # 3664
Seq. Net Income Change - - - - -


IOVA Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 413
Overall Market # 3328

Net Income per Employee Statistics
High Average Low
$ -10,686 $ -211,037 $ -461,172
(Sep 30 2013)   (Mar 31 2024)







Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-29T17:25:14+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.